Research & Development
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
6 October 2026 - India-based pharmaceutical companies Zydus Lifesciences Limited and MSN Laboratories Private Limited announced on Monday the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg an...
FDA approves second Reykjavik manufacturing suite for AVT02
5 October 2026 - Global biotechnology company Alvotech (NASDAQ: ALVO; STO: ALVO-SDB), which develops and manufactures biosimilar medicines, said on Monday it has received US Food and Drug Administrati...
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
5 October 2026 - Ractigen Therapeutics, a China-based, clinical-stage biotechnology company, announced on Saturday the presentation of positive first-in-human clinical data from its ongoing Phase I tr...
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
5 October 2026 - AnnJi Pharmaceutical Co Ltd (TPEx:7754), a Taiwan-based, clinical-stage drug development company focused on innovative small molecules, announced on Monday that it is proceeding with ...
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
2 October 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), which develops medicines across neuroscience and immunology, on Friday released new anal...
PearlMatrix P-15 Peptide Enhanced Bone Graft receives Medicare New Technology Add-on Payment (NTAP) status
2 October 2026 - Cerapedics Inc., a US-based, commercial-stage musculoskeletal company involved in bone repair, announced on Thursday that the Centers for Medicare & Medicaid Services (CMS) has gr...